HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

Abstract

Epigenetic mechanisms play an important role in the development and persistence of cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting epigenetic modes. Efficient anticancer drugs for the treatment of castration-resistant prostate cancer (CRPC) are sought, and approved HDAC inhibitors have shown promising results on the one hand and severe drawbacks on the other hand. Hence, ways to break the drug resistance mechanisms of existing HDAC inhibitors as well as the design of new promising HDAC inhibitors which can overcome the disadvantages of the classic HDAC inhibitors are of great importance. In this work, HDAC inhibitors with the potential to become a mainstay for the treatment of CRPC in the future as well as suitable combination treatments of HDAC inhibitors with other anticancer drugs leading to considerable synergistic effects in treated CRPCs are discussed.

Keywords

Histone deacetylases / HDAC inhibitors / castration-resistant prostate cancer / drug resistance

References

[1] Rawla P.Epidemiology of prostate cancer.World J Oncol2019;10:63-89 PMCID:PMC6497009

[2] Damodaran S,Jarrard DF.Newly diagnosed metastatic prostate cancer: has the paradigm changed?.Urol Clin North Am2017;44:611-21 PMCID:PMC6402766

[3] Sartor AO.Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.J Hematol Oncol2011;4:18 PMCID:PMC3102641

[4] Hellerstedt B.The current state of hormonal therapy for prostate cancer.CA Cancer J Clin2008;52:154-79

[5] Smith MR,Chowdhury S.Apalutamide treatment and metastasis-free survival in prostate cancer.N Engl J Med2018;378:1408-18

[6] Hussain M,Saad F.Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.N Engl J Med2018;378:2465-74 PMCID:PMC8288034

[7] Fizazi K,Tammela TL.Darolutamide in nonmetastatic, castration-resistant prostate cancer.N Engl J Med2019;380:1235-46

[8] Leung DK,Ng C.Novel strategies for treating castration-resistant prostate cancer.Biomedicines2021;9:339 PMCID:PMC8066514

[9] Scott LJ.Abiraterone acetate: a review in metastatic castration-resistant prostrate cancer.Drugs2017;77:1565-76

[10] Kornberg RD.Chromatin structure: a repeating unit of histone and DNA.Science1974;184:868-71

[11] Kornberg RD.Structure of chromatin.Annu Rev Biochem1977;46:931-54

[12] Ropero S.The role of histone deacetylases (HDACs) in human cancer.Mol Oncol2007;1:19-25 PMCID:PMC5543853

[13] New M,La Thangue NB.HDAC inhibitor-based therapies: can we interpret the code.Mol Oncol2012;6:637-56 PMCID:PMC5528347

[14] Singh BN,Hwa YL,Dowdy SC.Nonhistone protein acetylation as cancer therapy targets.Expert Rev Anticancer Ther2010;10:935-54 PMCID:PMC3273412

[15] Abbas A.The role of histone deacetylases in prostate cancer.Epigenetics2008;3:300-9 PMCID:PMC2683066

[16] Conteduca V,Yamada Y,Beltran H.Epigenetics in prostate cancer: clinical implications.Trans Androl Urol2021;10:3104-16 PMCID:PMC8350251

[17] Crea F,Mai A.The emerging role of histone lysine demethylases in prostate cancer.Mol Cancer2012;11:52 PMCID:PMC3441810

[18] Huang PH,Chou CC.Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases.Mol Pharmacol2011;79:197-206 PMCID:PMC3014276

[19] Orzan F,Pollani PL.Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.Neuropathol Appl Neurobiol2011;37:381-394

[20] Nebbioso A,Benedetti R.Trials with "epigenetic" drugs: an update.Mol Oncol2012;6:657-82 PMCID:PMC5528349

[21] Halkidou K,Cook S,Neal DE.Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.Prostate2004;59:177-89.

[22] Weichert W,Gekeler V.Histone deacetylases 1, 2, and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.Br J Cancer2008;98:604-10 PMCID:PMC2243142

[23] Welsbie DS,Chen Y.Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.Cancer Res2009;69:958-66 PMCID:PMC3219545

[24] Rana Z,Hanif M.Understanding failure and improving treatment using HDAC inhibitors for prostate cancer.Biomedicines2020;8:22 PMCID:PMC7168248

[25] Kong D,Bao B,Banerjee S.Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.PLoS ONE2012;7:e45045 PMCID:PMC3443231

[26] Ververis K,Karagiannis TC.Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.Biologics2013;7:47-60 PMCID:PMC3584656

[27] Gregoretti IV,Goodson HV.Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.J Mol Biol.2004;338:17-31

[28] Paris M,Binaschi M.Histone deacetylase inhibitors: from bench to bedside.J Med Chem2008;51:1505-29

[29] Schobert R.Multimodal HDAC inhibitors with improved anticancer activity.Curr Cancer Drug Targets2018;18:39-56

[30] Biersack B,Höpfner M.Anticancer properties of chimeric HDAC and kinase inhibitors.Semin Cancer Biol2020;

[31] Kaushik D,Isharwal S,Lin MF.Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.Ther Adv Urol2015;7:388-95 PMCID:PMC4647138

[32] Molife LR,Fong PC.Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).Ann Oncol2010;21:109-13

[33] Bradley D,Dunn R.Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.Cancer2009;115:5541-9 PMCID:PMC2917101

[34] Rathkopf D,Hussain A.A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.Cancer Chemother Pharmacol2013;72:537-44 PMCID:PMC3970811

[35] Rathkopf D,Ross R.A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC).J Clin Oncol2008;26:5152

[36] Ferrari A,Alumkal .A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy.J Clin Oncol2011;29:156

[37] Ferrari AC,Stein MN.Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer.Clin Cancer Res2019;25:52-63

[38] Eigl BJ,Winquist .A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.Invest New Drugs2015;33:969-76

[39] Tang S,Jiang J.Tumor suppressive maspin-sensitized prostate cancer to drug treatment through negative regulating androgen receptor expression.Front Cell Dev Biol2020;8:573820 PMCID:PMC7649228

[40] Fang Y,Robins D.Hsp90 regulates androgen receptor hormone binding affinity in vivo.J Biol Chem1996;271:28697-702

[41] Gravina GL,Muzi P.PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, Hsp90, and CRM1 in preclinical models of prostate cancer.Endocr Relat Cancer2013;20:321-37

[42] Chen L,Wang H.Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.Mol Cancer Ther2005;4:1311-9

[43] Shen L,Ramakrishnan S.Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.PLoS One2012;7:e30815 PMCID:PMC3267747

[44] Armstrong K,Leung HY.NF-κB activation upregulates fibroblast growth factor 8 expression in prostate cancer cells.Prostate2006;66:1223-34

[45] Xu W,Lu N.A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition.Cell Adh Migr2015;9:317-24 PMCID:PMC4594353

[46] Ruscetti M,Guo W.HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.Oncogene2016;35:3781-95 PMCID:PMC4896852

[47] Pellacani D,Frame FM.Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.Mol Cancer2011;10:94 PMCID:PMC3162587

[48] Fialova B,Gursky J,Kolar Z.Epigenetic modulation of AR expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5’-aza-2’-deoxycytidine.Oncol Rep2016;36:2365-74

[49] Pacheco MB,Lopes N.Hydralazine and panobinostat attenuate malignant properties of prostate cancer cell lines.Pharmaceuticals2021;14:670 PMCID:PMC8308508

[50] Felice F, Tombolini V, Marampon F, Musella A, Marchetti C. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.Drug Des Devel Ther2017;11:547-52 PMCID:PMC5338854

[51] Martin GA,Parikh K.A novel use of olaparib for the treatment of metastatic castration-recurrent prostate cancer.Pharmacotherapy2017;37:1406-14

[52] Chao OS.Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.Mol Cancer Res2014;12:1755-66

[53] Yin L,Peng Y.PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.J Exp Clin Cancer Res2018;37:153 PMCID:PMC6048811

[54] Park SE,Kim DE.Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signalin in castration-resistant prostate cancer.Invest New Drugs2018;36:195-205

[55] Pfeiffer MJ,Schalken JA.An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer.Prostate2010;70:1524-32

[56] Drake JM,Stoyanova T.Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.Proc Natl Acad Sci U S A2012;109:1643-8 PMCID:PMC3277127

[57] Vallo S,Stastny M.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH598 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.Invest New Drugs2013;31:265-72

[58] Cheng Y.Current development status of MEK inhibitors.Molecules2017;22:1551 PMCID:PMC6151813

[59] Corno C,Ciusani E.Synergistic interaction of histone deacetylase 6- and MEK-inhibitors in castration resistant prostate cancer cells.Front Cell Dev Biol2020;8:610 PMCID:PMC7365948

[60] Sabatini DM.mTOR and cancer: insights into a complex relationship.Nat Rev Cancer2006;6:729-34

[61] Sawyers CL.Will mTOR inhibitors make it as cancer drugs?.Cancer Cell2003;4:343-8

[62] Wedel S,Seibel JM.Inhibitory effects of the HDAC inhibitor valproic acidon prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.Life Sci2011;88:418-24

[63] Wedel S,Seibel JM.Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.Clin Exp Metastasis2011;28:479-91

[64] Tsaur I,Makarevic J.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dose interferon alpha in prostate cancer cells.J Cell Mol Med2015;19:1795-804

[65] Ellis L,Ramakrishnan S.Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.PLoS ONE2011;6:e27178 PMCID:PMC3210144

[66] Ellwood-Yen K,Wongvipat J.Myc-driven murine prostate cancer shares molecular features with human prostate tumors.Cancer Cell2003;4:223-38

[67] Balakumaran BS,Hsu DS.MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.Cancer Res2009;69:7803-10 PMCID:PMC2756305

[68] Holoch PA.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Eur J Pharmacol.2009;625:63-72 PMCID:PMC2783837

[69] Kasman L,Voelkel-Johnson C.The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.Cancer Gene Ther2007;14:327-34

[70] Kasman L,Voelkel-Johnson C.Histone deacetylase inhibitors restore cell surface expression of the Coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells.Prostate Cancer2012;2012:137163 PMCID:PMC3263646

[71] Chen Z,Yang X.Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer.Eur J Nucl Med Mol Imaging2021;48:53-66

[72] Fu RG,Sheng WB.Designing multi-targeted agents: an emerging anticancer drug discovery paradigm.Eur J Med Chem.2017;136:195-211

[73] Bérubé G.An overview of molecular hybrids in drug discovery.Exp Opin Drug Discov.2016;11:281-305

[74] Rosati R,Patki M.Hybrid enzalutamide derivatives with histone deacetylase inhibitor activity decrease heat shock protein 90 and androgen receptor levels and inhibit viability in enzalutamide-resistant prostate cancer cells.Mol Pharmacol2016;90:225-37 PMCID:PMC4998664

[75] Hu W-Y,Chen B.Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.Prostate2019;79:1166-79

[76] Lai C-J,Tao X.CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.Cancer Res2010;70:3647-56

[77] Sun H,Szafran AT,Marcelli M.CUDC-101, a novel inhibitor of full-length androgen receptor (flAR) and androgen receptor variant 7 (AR-V7) activity: mechanisms of action and in vivo efficacy.HORM CANC2016;7:196-210

[78] Li X,Cameron MD.Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.Drug Metab Dispos2010;38:1238-45 PMCID:PMC3202369

[79] Gass-Jégu F,Gairard-Dory AC.Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review.Lung Cancer2016;99:76-78

[80] Galloway TJ,Covelas AD.A phase I study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma.Clin Cancer Res2015;21:1566-73 PMCID:PMC6607903

[81] Wu CP,Su CY.Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.Biochem Pharmacol2014;92:567-76

[82] Yanase K,Asada S,Imai Y.Gefitinib reverses breast cancer resistance protein-mediated drug resistance.Mol Cancer Ther2004;3:1119-25

[83] Leggas M,Zhuang Y.Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.Cancer Res2006;66:4802-7

[84] Goehringer N,Peng Y.Anticancer activity and mechanisms of action of new chimeric EGFR/HDAC-inhibitors.Int J Mol Sci2021;22:8432 PMCID:PMC8395095

[85] Qian C,Bao R.Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res2012;18:4104-13

[86] Hu C,Bai S.CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: antitumor activity and molecular mechanism of action.J Cell Mol Med2020;24:7239-53 PMCID:PMC7339177

[87] Landsburg DJ,Ramchandren R.Fimepinostat (CUDC-907) in patients with relapsed diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.Br J Haematol2021;195:201-9

[88] Wu CP,Hsiao SH.Human ATP-Binding Cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase.Mol Pharmaceutics2016;13:784-94